Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial. (PubMed, Lancet Haematol) - Oct 2, 2026 - P3 | "Felzartamab plus lenalidomide-dexamethasone significantly prolonged progression-free survival compared with lenalidomide-dexamethasone alone, supporting felzartamab plus lenalidomide-dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma."
Clinical • Journal • P3 data • Cardiovascular • CNS Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Leukopenia • Multiple Myeloma • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Thrombocytopenia
|
|
Andrew X Zhu; Baijun Fang; Bin Liang; Bing Chen; Chengcheng Fu; Chieh-Lin Teng; Chunkang Chang; Depei Wu; Fangbing Zhu; Haiyan He; Hao-Yuan Wang; Hong Liu; Hongxiang Wang; Hui Zhou; Huijing Wu; Jianqing Mi; Jie Jin; Jingjing Shang; Jinwen Huang; Juan Li; Jun Luo; Lijuan Chen; Liye Zhong; Minfang Wu; Ming-Chung Wang; Mingshen Dai; Pengyun Zeng; Ping Yang; Po-Shen Ko; Qingming Wang; Rong Zhan; Shang-Yi Huang; Shunqing Wang; Suijing Wu; Sujun Gao; Tonghua Yang; Weijun Fu; Wenming Chen; Xi Chen; Xin Du; Yafei Wang; Yajun Li; Yaming Xi; Yan Li; Yan Liu; Yanli Yang; Yongqiang Wei; Yuan Meng; Zeping Zhou; Zhen Cai; Zhongjun Xia; Zhongxia Huang; Zonghong Shao
|